Contraindications of incretin therapy: difference between revisions
Diff·revision 10 → 11·10:58, 31 Mar 2025
Difference between revision 10 and revision 11 of Contraindications of incretin therapy. 4 lines changed; the page grew by 726 bytes.
| Revision 10 — 13:44, 8 Mar 2025 INN_Ingrid (talk) expand §Scope of this article 3,570 bytes +162 | Revision 11 — 10:58, 31 Mar 2025 HypoHildur (talk) add the perioperative consideration with the society guidance it comes from 4,296 bytes +726 | ||
|---|---|---|---|
| 31 | Renal considerations are indirect for most of this class: the peptides are not renally cleared to a degree requiring dose adjustment, but persistent vomiting and reduced intake can precipitate acute kidney injury in someone with limited reserve.{{r|ada2024}} | 31 | Renal considerations are indirect for most of this class: the peptides are not renally cleared to a degree requiring dose adjustment, but persistent vomiting and reduced intake can precipitate acute kidney injury in someone with limited reserve.{{r|ada2024}} |
| 32 | 32 | ||
| + | 33 | Interaction with oral medicines is a rate rather than an extent effect for most drugs, arising from delayed emptying. See Drug interaction with oral absorption.{{r|nauck2016}} Trial populations excluded several of the groups listed above, so the evidence in them is correspondingly thin.{{r|wilding2021}} | |
| + | 34 | ||
| 33 | == References == | 35 | == References == |
| 34 | {{reflist}} | 36 | {{reflist}} |
| 35 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 37 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 36 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 38 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 39 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> | |
| + | 40 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | |
| 37 | 41 | ||
| 38 | == See also == | 42 | == See also == |